Chandler Park, MD, MSc, FACP

Articles

Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff

December 13th 2024

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

December 12th 2024

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

December 12th 2024

Drs Park and Liu discuss the use of amivantamab plus lazertinib in EGFR-mutated non–small cell lung cancer.

Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham

December 11th 2024

Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

December 10th 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

December 9th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Recapping the Latest in AML With Dr Eunice Wang

December 8th 2024

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

November 27th 2024

Hear Chandler Park, MD and Stephen Liu, MD, explore advancements in EGFR-mutated NSCLC treatment, including TKI strategies, emerging therapies prioritizing a patient-centric approach.

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

November 6th 2024

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

October 30th 2024

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

October 16th 2024

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

October 2nd 2024

Drs Park and Patil discuss the evolving small cell lung cancer treatment paradigm, focusing on PCI, immune checkpoint inhibitors, and recent study data.

Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024

September 18th 2024

In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial.

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

September 4th 2024

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

August 21st 2024

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Park and Grivas Expand on Treatment Updates in Bladder Cancer

August 7th 2024

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

July 10th 2024

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting

June 27th 2024

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.